Oral Fingolimod (FTY720) for Relapsing Multiple SclerosisLudwig Kappos, Ernst W. Radue, Jack P. Antel et al.|New England Journal of Medicine|2006Cited by 1.1k
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysisLudwig Kappos, Massimo Filippi, David Moeri et al.|The Lancet|1999Cited by 500
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disabilityStefan D. Roosendaal, Jeroen J.G. Geurts, Kerstin Bendfeldt et al.|Multiple Sclerosis Journal|2011Cited by 190
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resultsCristoforo Comi, Paul O’Connor, Xavier Montalbán et al.|Multiple Sclerosis Journal|2009Cited by 158
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trialsFrederik Barkhof, Massimo Filippi, Jack H. Simon et al.|Nature Reviews Neurology|2011Cited by 76